Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature

Celine Aerts, Temmy Sunyoto, Fabrizio Tediosi, Elisa Sicuri

    Research output: Contribution to journalA1: Web of Science-article

    Abstract

    Pharmaceutical companies are reluctant to invest in research and development (R&D) of products for neglected tropical diseases (NTDs) mainly due to the low ability-to-pay of health insurance systems and of potential consumers. The available preventive and curative interventions for NTDs mostly rely on old technologies and products that are often not adequate. Moreover, NTDs mostly affect populations living in remote rural areas and conflict zones, thereby hampering access to healthcare. The challenges posed by NTDs have led to the proliferation of a variety of public-private partnerships (PPPs) in the last decades. We conducted a systematic review to assess the functioning and impact of these partnerships on the development of and access to better technologies for NTDs. Our systematic review revealed a clear lack of empirical assessment of PPP5: we could not find any impact evaluation analyses, while these are crucial to realize the full potential of PPP5 and to progress further towards NTDs elimination. (C) 2017 Elsevier B.V. All rights reserved.

    Original languageEnglish
    JournalHealth Policy
    Volume121
    Issue number7
    Pages (from-to)745-754
    Number of pages10
    ISSN0168-8510
    DOIs
    Publication statusPublished - 2017

    Keywords

    • Public-private partnerships
    • Neglected tropical diseases
    • Health economics
    • Public health
    • Research and development
    • PRODUCT DEVELOPMENT PARTNERSHIPS
    • RESEARCH-AND-DEVELOPMENT
    • DRUG DISCOVERY
    • PHARMACEUTICAL INNOVATION
    • RESEARCH CAPACITY
    • HUMAN HOOKWORM
    • HEALTH EQUITY
    • VACCINES
    • ONCHOCERCIASIS
    • AMERICA

    Cite this